Information  X 
Enter a valid email address

Nuformix PLC (NFX)

  Print      Mail a friend

Tuesday 22 December, 2020

Nuformix PLC

Appointment of Broker

RNS Number : 4400J
Nuformix PLC
22 December 2020
 

22 December 2020

 

Nuformix plc

(the "Company" or the "Group")

 

Appointment of Broker

 

Nuformix plc (LSE:NFX), a drug re-purposing specialist, is pleased to announce the appointment of Allenby Capital Limited as the Company's sole Broker with effect from today.

 

Allenby Capital currently advise over 60 corporate clients listed on the London Stock Exchange main market, AIM or Aquis exchanges. Allenby Capital will provide access for Nuformix to a broad spectrum of investors including institutional investors, family offices, private client brokers and high net worth individuals.

 

 

Enquiries:

 

Nuformix plc

+44 (0)1223 627222

Dr Anne Brindley, CEO

 

Fleur Wood, Investor Relations

Email: [email protected]

 

 

 

 

Allenby Capital Limited

+44 (0)20 3328 5656

Tim Sohal / Matt Butlin (Sales and Corporate Broking)

Nick Athanas (Corporate Finance)

 

 

 

About Nuformix plc:

 

Nuformix is a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop new novel medicines which provide therapeutic and commercial advantages to the currently available drug form. Nuformix's model of repurposing drugs utilises many technologies but is focussed on its acknowledged expertise in the use of cocrystal technology through which the Group has developed and patented novel forms of small molecules. Its platform is not therapy-specific but instead has broad application across a wide range of indications. Using its technology, the Group is developing proprietary medicines for its own development pipeline and in partnership with pharmaceutical and biotech companies.

 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information please visit www.nuformix.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPFEUFAFESSEDE

a d v e r t i s e m e n t